Immunotherapy and targeted drug for eyelid cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs—sintilimab, which helps the immune system fight cancer, and disitamab vedotin, which targets cancer cells directly—for people with a rare type of eyelid cancer that has not spread far. The goal is to see if this treatment can shrink the tumor before surgery, making it easier to remove.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have been diagnosed with sebaceous gland carcinoma of the eyelid that is locally advanced (has grown but not spread to distant parts of the body).
- Your doctor thinks the tumor can be removed with surgery, and you are willing to have surgery.
- You are generally healthy and able to care for yourself (ECOG score 0 or 1).
- Your blood counts, liver, kidney, and clotting functions are within acceptable ranges.
- You have not had prior treatment with anti-PD-1, anti-PD-L1, or anti-HER2 therapies, and you do not have active autoimmune diseases or serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs, GV20-0251 and Sintilimab, given before surgery for head and neck cancer. The goal is to see if this combination can shrink tumors and make surgery more effective.
This Phase 3 trial studies whether adding sintilimab (an immunotherapy medicine) after surgery improves outcomes for people with locally advanced esophageal squamous cell carcinoma. It compares sintilimab plus a chemo/RT plan versus the same chemo/RT plan without immunotherapy.
This trial tests two drugs together—vorolanib (a pill that targets blood vessels in tumors) and sintilimab (an immunotherapy that helps your immune system fight cancer)—for people with advanced kidney cancer whose prior immunotherapy combination stopped working.
This trial studies adding an immunotherapy drug (sintilimab) to standard chemotherapy before surgery for resectable squamous non-small cell lung cancer. It aims to shrink the tumor and improve outcomes, while still keeping the cancer operable.
This trial tests a new combination of two drugs (sintilimab and anlotinib) for people with extensive-stage small cell lung cancer that has gotten worse after prior immunotherapy. The goal is to see if this combination can help control the cancer.
This trial tests whether adding an immune checkpoint inhibitor (a drug that helps your immune system fight cancer) as maintenance therapy after chemoradiotherapy improves outcomes for people with locally advanced head and neck cancer. It specifically looks at a marker in your blood (CD8Tex cells) to see if you might benefit.
Hear when a new Sebaceous Gland Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.